Applications of genome-wide screening and systems biology approaches in drug repositioning

Elyas Mohammadi; Rui Benfeitas; Hasan Turkez; Jan Boren; Jens Nielsen; Mathias Uhlen; Adil Mardinoglu

doi:10.3390/cancers12092694

Applications of genome-wide screening and systems biology approaches in drug repositioning

Elyas Mohammadi, Rui Benfeitas, Hasan Turkez, Jan Boren, Jens Nielsen, Mathias Uhlen, Adil Mardinoglu^*

^*Corresponding author for this work

Centre for Host Microbiome Interactions

Research output: Contribution to journal › Review article › peer-review

16 Citations (Scopus)

Abstract

Modern drug discovery through de novo drug discovery entails high financial costs, low success rates, and lengthy trial periods. Drug repositioning presents a suitable approach for overcoming these issues by re-evaluating biological targets and modes of action of approved drugs. Coupling high-throughput technologies with genome-wide essentiality screens, network analysis, genome-scale metabolic modeling, and machine learning techniques enables the proposal of new drug–target signatures and uncovers unanticipated modes of action for available drugs. Here, we discuss the current issues associated with drug repositioning in light of curated high-throughput multi-omic databases, genome-wide screening technologies, and their application in systems biology/medicine approaches.

Original language	English
Article number	2694
Pages (from-to)	1-24
Number of pages	24
Journal	Cancers
Volume	12
Issue number	9
DOIs	https://doi.org/10.3390/cancers12092694
Publication status	Published - Sept 2020

Keywords

Drug repositioning
Genomic screens
Machine learning
Systems medicine
Systems pharmacology

Access to Document

10.3390/cancers12092694

Cite this

@article{7effb85ee79a454a9608d75026b0322c,

title = "Applications of genome-wide screening and systems biology approaches in drug repositioning",

abstract = "Modern drug discovery through de novo drug discovery entails high financial costs, low success rates, and lengthy trial periods. Drug repositioning presents a suitable approach for overcoming these issues by re-evaluating biological targets and modes of action of approved drugs. Coupling high-throughput technologies with genome-wide essentiality screens, network analysis, genome-scale metabolic modeling, and machine learning techniques enables the proposal of new drug–target signatures and uncovers unanticipated modes of action for available drugs. Here, we discuss the current issues associated with drug repositioning in light of curated high-throughput multi-omic databases, genome-wide screening technologies, and their application in systems biology/medicine approaches.",

keywords = "Drug repositioning, Genomic screens, Machine learning, Systems medicine, Systems pharmacology",

author = "Elyas Mohammadi and Rui Benfeitas and Hasan Turkez and Jan Boren and Jens Nielsen and Mathias Uhlen and Adil Mardinoglu",

year = "2020",

month = sep,

doi = "10.3390/cancers12092694",

language = "English",

volume = "12",

pages = "1--24",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "9",

}

TY - JOUR

T1 - Applications of genome-wide screening and systems biology approaches in drug repositioning

AU - Mohammadi, Elyas

AU - Benfeitas, Rui

AU - Turkez, Hasan

AU - Boren, Jan

AU - Nielsen, Jens

AU - Uhlen, Mathias

AU - Mardinoglu, Adil

PY - 2020/9

Y1 - 2020/9

N2 - Modern drug discovery through de novo drug discovery entails high financial costs, low success rates, and lengthy trial periods. Drug repositioning presents a suitable approach for overcoming these issues by re-evaluating biological targets and modes of action of approved drugs. Coupling high-throughput technologies with genome-wide essentiality screens, network analysis, genome-scale metabolic modeling, and machine learning techniques enables the proposal of new drug–target signatures and uncovers unanticipated modes of action for available drugs. Here, we discuss the current issues associated with drug repositioning in light of curated high-throughput multi-omic databases, genome-wide screening technologies, and their application in systems biology/medicine approaches.

AB - Modern drug discovery through de novo drug discovery entails high financial costs, low success rates, and lengthy trial periods. Drug repositioning presents a suitable approach for overcoming these issues by re-evaluating biological targets and modes of action of approved drugs. Coupling high-throughput technologies with genome-wide essentiality screens, network analysis, genome-scale metabolic modeling, and machine learning techniques enables the proposal of new drug–target signatures and uncovers unanticipated modes of action for available drugs. Here, we discuss the current issues associated with drug repositioning in light of curated high-throughput multi-omic databases, genome-wide screening technologies, and their application in systems biology/medicine approaches.

KW - Drug repositioning

KW - Genomic screens

KW - Machine learning

KW - Systems medicine

KW - Systems pharmacology

UR - http://www.scopus.com/inward/record.url?scp=85091672930&partnerID=8YFLogxK

U2 - 10.3390/cancers12092694

DO - 10.3390/cancers12092694

M3 - Review article

AN - SCOPUS:85091672930

SN - 2072-6694

VL - 12

SP - 1

EP - 24

JO - Cancers

JF - Cancers

IS - 9

M1 - 2694

ER -

Applications of genome-wide screening and systems biology approaches in drug repositioning

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this